It’s an exciting time on Wall Street. Broader market indices, including the S&P 500 and Nasdaq 100, are hovering near all-time highs. But while leading stocks continue to deliver lucrative returns, many businesses have gone through a volatile summer. Those companies with shaky fundamentals, such as special purpose acquisition companies (SPSCs) or unprofitable tech firms, have recently…

At one point, investors loved Zomedica (NYSE:ZOM). Giddy with anticipation, investors sent ZOM stock from six cents to $2.90 for a win of 4,733% in about two months. Every $1,000 risked would have been worth more than $48,000. Source: Postmodern Studio / Shutterstock.com The stock could do no wrong. Up it went, fueled by a combination…

Zomedica Corp (NYSE:ZOM) announced not only results for Q2 on Aug. 11 but also a new business model. So far nothing has been working to advance the sale of its veterinary Truforma instruments. If the new business plan works, ZOM stock might be worth more than its Sept. 2 opening price of 61.25 cents per…

In recent days, meme stocks have turned green in a big way. Shares of GameStop (NYSE:GME) and AMC Entertainment (NYSE:AMC) are both up big over the past week. Investors in Zomedica (NYSE:ZOM) and ZOM stock appear to be riding these coattails. Source: Postmodern Studio / Shutterstock.com Indeed, ZOM stock has surged from under 50 cents per…

At one point, Zomedica (NYSE:ZOM) could do no wrong. ZOM stock would explode some 2,900% from its November 2020 lows. The company was nearing commercialization of its point-of-care diagnostic product. Even the pet industry was howling about the opportunity. Source: Postmodern Studio / Shutterstock.com Nowadays, Zomedica has become a slow-motion train wreck. In fact, the last…

Global markets have been in a tough spot of late due to a lack of clarity on central banking policy. Investors are tentative, as many assets are trading at high multiples after a tremendous bull run. The May selloff, which is common under normal market circumstances, has now extended into late June. From penny stocks…

With Zomedica’s  (NYSE:ZOM) new Truforma diagnostic tool possibly facing a great deal of entrenched competition, the outlook of ZOM stock is, at best, difficult to determine. Meanwhile, the shares have a very high valuation. Source: didesign021 / Shutterstock.com A diagnostic product meant to be used by veterinarians, Truforma measures the amount of T4 and TSH…

With Zomedica’s  (NYSE:ZOM) new Truforma diagnostic tool possibly facing a great deal of entrenched competition, the outlook of ZOM stock is, at best, difficult to determine. Meanwhile, the shares have a very high valuation. Source: didesign021 / Shutterstock.com A diagnostic product meant to be used by veterinarians, Truforma measures the amount of T4 and TSH…